tiprankstipranks
Trending News
More News >
Hims & Hers Health (DE:82W)
FRANKFURT:82W
Germany Market

Hims & Hers Health (82W) Stock Forecast & Price Target

Compare
36 Followers
See the Price Targets and Ratings of:

82W Analyst Ratings

Moderate Buy
14Ratings
Moderate Buy
4 Buy
10 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Hims
& Hers Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

82W Stock 12 Month Forecast

Average Price Target

€22.71
▲(4.41% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is €22.71 with a high forecast of €30.57 and a low forecast of €14.85. The average price target represents a 4.41% change from the last price of €21.75.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"€13","56":"€56","23.75":"€23.8","34.5":"€34.5","45.25":"€45.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30.57075595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€30.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":22.70970442,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€22.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.84865289,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€14.85</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,23.75,34.5,45.25,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14,15.274673534615385,16.54934706923077,17.824020603846154,19.09869413846154,20.373367673076924,21.64804120769231,22.92271474230769,24.19738827692308,25.47206181153846,26.746735346153848,28.02140888076923,29.296082415384614,{"y":30.57075595,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14,14.669977263076923,15.339954526153846,16.00993178923077,16.679909052307693,17.349886315384616,18.01986357846154,18.689840841538462,19.359818104615385,20.02979536769231,20.699772630769232,21.369749893846155,22.039727156923078,{"y":22.70970442,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14,14.065280991538462,14.130561983076923,14.195842974615385,14.261123966153846,14.326404957692308,14.39168594923077,14.456966940769231,14.522247932307693,14.587528923846154,14.652809915384616,14.718090906923077,14.783371898461539,{"y":14.84865289,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.38,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.8,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29.24,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":50.9,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":39.95,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":55.28,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.56,"date":1756684800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":48.04,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":41.15,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":33.16,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":29,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":23.1,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":14,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€30.57Average Price Target€22.71Lowest Price Target€14.85
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on DE:82W
Leerink Partners
Leerink Partners
€15.29€21.84
Hold
0.40%
Upside
Reiterated
03/16/26
Hims & Hers price target raised to $25 from $17.50 at LeerinkHims & Hers price target raised to $25 from $17.50 at Leerink
Barclays
€21.84€25.33
Buy
16.46%
Upside
Assigned
03/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Medtronic (NYSE: MDT)
Bank of America Securities Analyst forecast on DE:82W
Bank of America Securities
Bank of America Securities
€10.92€20.09
Hold
-7.64%
Downside
Upgraded
03/10/26
Hims & Hers upgraded to Neutral from Underperform at BofAHims & Hers upgraded to Neutral from Underperform at BofA
Deutsche Bank  Analyst forecast on DE:82W
Deutsche Bank
Deutsche Bank
€21.84€24.46
Hold
12.44%
Upside
Reiterated
03/10/26
Hims & Hers price target raised to $28 from $25 at Deutsche BankHims & Hers price target raised to $28 from $25 at Deutsche Bank
Citi
€11.57€20.96
Hold
-3.62%
Downside
Upgraded
03/10/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)
Truist Financial Analyst forecast on DE:82W
Truist Financial
Truist Financial
Hold
Reiterated
03/10/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), ARS Pharmaceuticals (NASDAQ: SPRY) and Revolution Medicines (NASDAQ: RVMD)
Nephron Analyst forecast on DE:82W
Unknown Analyst
Nephron
Not Ranked
Nephron
€30.57
Buy
40.56%
Upside
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
Canaccord Genuity Analyst forecast on DE:82W
Canaccord Genuity
Canaccord Genuity
€26.2
Buy
20.48%
Upside
Reiterated
03/09/26
Re-Rating Hims & Hers: Novo Nordisk Partnership De-Risks GLP-1 Exposure and Supports Further Multiple Expansion
Morgan Stanley Analyst forecast on DE:82W
Morgan Stanley
Morgan Stanley
€18.34
Hold
-15.67%
Downside
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)
Needham
€26.2
Buy
20.48%
Upside
Upgraded
03/09/26
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Hims & Hers Health (NYSE: HIMS)
BTIG
Hold
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Evercore ISI Analyst forecast on DE:82W
Evercore ISI
Evercore ISI
€28.82€20.96
Hold
-3.62%
Downside
Reiterated
02/24/26
Hims & Hers price target lowered to $24 from $33 at Evercore ISIHims & Hers price target lowered to $24 from $33 at Evercore ISI
KeyBanc
Hold
Reiterated
02/24/26
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Kyntra Bio (NASDAQ: KYNB) and Hims & Hers Health (NYSE: HIMS)
TD Cowen Analyst forecast on DE:82W
TD Cowen
TD Cowen
€17.47€14.85
Hold
-31.73%
Downside
Reiterated
02/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Summit Therapeutics (NASDAQ: SMMT)
Mizuho Securities Analyst forecast on DE:82W
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
€26.2
Sell
20.48%
Upside
Reiterated
11/18/25
Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on DE:82W
Leerink Partners
Leerink Partners
€15.29€21.84
Hold
0.40%
Upside
Reiterated
03/16/26
Hims & Hers price target raised to $25 from $17.50 at LeerinkHims & Hers price target raised to $25 from $17.50 at Leerink
Barclays
€21.84€25.33
Buy
16.46%
Upside
Assigned
03/11/26
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Medtronic (NYSE: MDT)
Bank of America Securities Analyst forecast on DE:82W
Bank of America Securities
Bank of America Securities
€10.92€20.09
Hold
-7.64%
Downside
Upgraded
03/10/26
Hims & Hers upgraded to Neutral from Underperform at BofAHims & Hers upgraded to Neutral from Underperform at BofA
Deutsche Bank  Analyst forecast on DE:82W
Deutsche Bank
Deutsche Bank
€21.84€24.46
Hold
12.44%
Upside
Reiterated
03/10/26
Hims & Hers price target raised to $28 from $25 at Deutsche BankHims & Hers price target raised to $28 from $25 at Deutsche Bank
Citi
€11.57€20.96
Hold
-3.62%
Downside
Upgraded
03/10/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)
Truist Financial Analyst forecast on DE:82W
Truist Financial
Truist Financial
Hold
Reiterated
03/10/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), ARS Pharmaceuticals (NASDAQ: SPRY) and Revolution Medicines (NASDAQ: RVMD)
Nephron Analyst forecast on DE:82W
Unknown Analyst
Nephron
Not Ranked
Nephron
€30.57
Buy
40.56%
Upside
Upgraded
03/09/26
Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research
Canaccord Genuity Analyst forecast on DE:82W
Canaccord Genuity
Canaccord Genuity
€26.2
Buy
20.48%
Upside
Reiterated
03/09/26
Re-Rating Hims & Hers: Novo Nordisk Partnership De-Risks GLP-1 Exposure and Supports Further Multiple Expansion
Morgan Stanley Analyst forecast on DE:82W
Morgan Stanley
Morgan Stanley
€18.34
Hold
-15.67%
Downside
Reiterated
03/09/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)
Needham
€26.2
Buy
20.48%
Upside
Upgraded
03/09/26
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Hims & Hers Health (NYSE: HIMS)
BTIG
Hold
Reiterated
03/05/26
Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)
Evercore ISI Analyst forecast on DE:82W
Evercore ISI
Evercore ISI
€28.82€20.96
Hold
-3.62%
Downside
Reiterated
02/24/26
Hims & Hers price target lowered to $24 from $33 at Evercore ISIHims & Hers price target lowered to $24 from $33 at Evercore ISI
KeyBanc
Hold
Reiterated
02/24/26
Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Kyntra Bio (NASDAQ: KYNB) and Hims & Hers Health (NYSE: HIMS)
TD Cowen Analyst forecast on DE:82W
TD Cowen
TD Cowen
€17.47€14.85
Hold
-31.73%
Downside
Reiterated
02/23/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Summit Therapeutics (NASDAQ: SMMT)
Mizuho Securities Analyst forecast on DE:82W
Unknown Analyst
Mizuho Securities
Not Ranked
Mizuho Securities
€26.2
Sell
20.48%
Upside
Reiterated
11/18/25
Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months
xxx
Success Rate
9/12 ratings generated profit
75%
Average Return
+26.96%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +26.96% per trade.
1 Year
Success Rate
7/9 ratings generated profit
78%
Average Return
+35.73%
Copying Glen Santangelo's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +35.73% per trade.
2 Years
xxx
Success Rate
7/9 ratings generated profit
78%
Average Return
+37.00%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +37.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

82W Analyst Recommendation Trends

Rating
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Strong Buy
2
1
1
6
7
Buy
1
1
1
1
3
Hold
14
13
12
20
28
Sell
16
13
13
12
9
Strong Sell
2
2
0
0
0
total
35
30
27
39
47
In the current month, 82W has received 10 Buy Ratings, 28 Hold Ratings, and 9 Sell Ratings. 82W average Analyst price target in the past 3 months is 22.71.
Each month's total comprises the sum of three months' worth of ratings.

82W Financial Forecast

82W Earnings Forecast

Next quarter’s earnings estimate for 82W is <€0.01 with a range of -€0.18 to €0.13. The previous quarter’s EPS was €0.07. 82W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.
Next quarter’s earnings estimate for 82W is <€0.01 with a range of -€0.18 to €0.13. The previous quarter’s EPS was €0.07. 82W beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.

82W Sales Forecast

Next quarter’s sales forecast for 82W is €530.51M with a range of €523.52M to €544.28M. The previous quarter’s sales results were €531.65M. 82W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.
Next quarter’s sales forecast for 82W is €530.51M with a range of €523.52M to €544.28M. The previous quarter’s sales results were €531.65M. 82W beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year 82W has Performed in-line its overall industry.

82W Stock Forecast FAQ

What is DE:82W’s average 12-month price target, according to analysts?
Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 22.71.
    What is DE:82W’s upside potential, based on the analysts’ average price target?
    Hims & Hers Health has 4.41% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Hims & Hers Health a Buy, Sell or Hold?
          Hims & Hers Health has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.
            What is Hims & Hers Health’s share price target?
            The average share price target for Hims & Hers Health is 22.71. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €30.57 ,and the lowest forecast is €14.85. The average share price target represents 4.41% Increase from the current price of €21.75.
              What do analysts say about Hims & Hers Health?
              Hims & Hers Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of Hims & Hers Health?
                To buy shares of DE:82W, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.